Development of Acute Myocardial Infarction Mortality and Readmission Models for Public Reporting on Hospital Performance in Canada

Dennis T. Ko, Tareq Ahmed, Peter C. Austin, Warren J. Cantor, Paul Dorian, Michael Goldfarb, Yanyan Gong, Michelle M. Graham, Jing Gu, Nathaniel M. Hawkins, Thao Huynh, Karin H. Humphries, Maria Koh, Yoan Lamarche, Laurie J. Lambert, Patrick R. Lawler, Jean Francois Légaré, Hung Q. Ly, Feng Qiu, Ata ur Rehman QuraishiDerek Y. So, Robert C. Welsh, Harindra C. Wijeysundera, Graham Wong, Andrew T. Yan, Yana Gurevich

Résultat de recherche: Articleexamen par les pairs

11 Citations (Scopus)

Résumé

Background: Given changes in the care and outcomes of acute myocardial infarction (AMI) patients over the past several decades, we sought to develop prediction models that could be used to generate accurate risk-adjusted mortality and readmission outcomes for hospitals in current practice across Canada. Methods: A Canadian national expert panel was convened to define appropriate AMI patients for reporting and develop prediction models. Preliminary candidate variable evaluation was conducted using Ontario patients hospitalized with a most responsible diagnosis of AMI from April 1, 2015 to March 31, 2018. National data from the Canadian Institute for Health Information was used to develop AMI prediction models. The main outcomes were 30-day all-cause in-hospital mortality and 30-day urgent all-cause readmission. Discrimination of these models (measured by c-statistics) was compared with that of existing Canadian Institute for Health Information models in the same study cohort. Results: The AMI mortality model was assessed in 54,240 Ontario AMI patients and 153,523 AMI patients across Canada. We observed a 30-day in-hospital mortality rate of 6.3%, and a 30-day all-cause urgent readmission rate of 10.7% in Canada. The final Canadian AMI mortality model included 12 variables and had a c-statistic of 0.834. For readmission, the model had 13 variables and a c-statistic of 0.679. Discrimination of the new AMI models had higher c-statistics compared with existing models (c-statistic 0.814 for mortality; 0.673 for readmission). Conclusions: In this national collaboration, we developed mortality and readmission models that are suitable for profiling performance of hospitals treating AMI patients in Canada.

Langue d'origineEnglish
Pages (de-à)1051-1059
Nombre de pages9
JournalCJC Open
Volume3
Numéro de publication8
DOI
Statut de publicationPublished - août 2021

Note bibliographique

Funding Information:
This study was supported by the ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES, or the MOHLTC, is intended or should be inferred. Parts of this material are based on data and information compiled and provided by CIHI. The analyses, conclusions, opinions and statements expressed herein are those of the authors, and not necessarily those of CIHI. This study was undertaken with involvement by the Canadian Cardiovascular Society Quality Reporting Steering Committee and is endorsed by the Canadian Cardiovascular Society.

Funding Information:
Dr Patrick Lawler has received consulting fees from Novartis. Dr Welsh has received research grants from Astra Zeneca, Bayer, Boehringer Ingelheim, and Pfizer, and personal fees from Bayer and Quidel. The other authors have no conflicts of interest to disclose.

Funding Information:
This study was supported by the ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES, or the MOHLTC, is intended or should be inferred. Parts of this material are based on data and information compiled and provided by CIHI. The analyses, conclusions, opinions and statements expressed herein are those of the authors, and not necessarily those of CIHI. This study was undertaken with involvement by the Canadian Cardiovascular Society Quality Reporting Steering Committee and is endorsed by the Canadian Cardiovascular Society. This study was funded by a Foundation grant (FDN 154333) from the Canadian Institutes of Health Research (CIHR) awarded to Dr Ko. Dr Ko is supported by the Jack Tu Chair in Cardiovascular Outcomes Research. Dr Austin is supported by a Mid-Career Award from the Heart and Stroke Foundation of Canada (HSFC). Dr Lee is supported by the Ted Rogers Chair in Heart Function Outcomes. Dr Wijeysundera is supported by a Clinician Scientist Award from HSFC. Dr Patrick Lawler has received consulting fees from Novartis. Dr Welsh has received research grants from Astra Zeneca, Bayer, Boehringer Ingelheim, and Pfizer, and personal fees from Bayer and Quidel. The other authors have no conflicts of interest to disclose.

Funding Information:
This study was funded by a Foundation grant (FDN 154333) from the Canadian Institutes of Health Research (CIHR) awarded to Dr Ko. Dr Ko is supported by the Jack Tu Chair in Cardiovascular Outcomes Research. Dr Austin is supported by a Mid-Career Award from the Heart and Stroke Foundation of Canada (HSFC) . Dr Lee is supported by the Ted Rogers Chair in Heart Function Outcomes . Dr Wijeysundera is supported by a Clinician Scientist Award from HSFC.

Publisher Copyright:
© 2021 The Authors

ASJC Scopus Subject Areas

  • Cardiology and Cardiovascular Medicine

PubMed: MeSH publication types

  • Journal Article

Empreinte numérique

Plonger dans les sujets de recherche 'Development of Acute Myocardial Infarction Mortality and Readmission Models for Public Reporting on Hospital Performance in Canada'. Ensemble, ils forment une empreinte numérique unique.

Citer